167 related articles for article (PubMed ID: 1511432)
21. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
[TBL] [Abstract][Full Text] [Related]
22. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS
Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741
[TBL] [Abstract][Full Text] [Related]
23. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
24. Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro.
Cadieux PA; Mikolajczak SA; Reeves J; Strathdee C; Reid G; Panchal CJ; Clarke MW
Cancer Invest; 2006; 24(3):246-55. PubMed ID: 16809150
[TBL] [Abstract][Full Text] [Related]
25. Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor.
Jordan VC; Gosden B
J Steroid Biochem; 1983 Sep; 19(3):1249-58. PubMed ID: 6684713
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.
Smolev JK; Heston WD; Scott WW; Coffey DS
Cancer Treat Rep; 1977; 61(2):273-87. PubMed ID: 872132
[TBL] [Abstract][Full Text] [Related]
27. Chlropyrifos-methyl shows anti-androgenic activity without estrogenic activity in rats.
Kang HG; Jeong SH; Cho JH; Kim DG; Park JM; Cho MH
Toxicology; 2004 Jul; 199(2-3):219-30. PubMed ID: 15147795
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.
Desai D; Sinha I; Null K; Wolter W; Suckow MA; King T; Amin S; Sinha R
Int J Cancer; 2010 Jul; 127(1):230-8. PubMed ID: 19918950
[TBL] [Abstract][Full Text] [Related]
29. The effects of a brain-enhanced estradiol delivery system on testosterone and androgen-dependent tissues. II. The role of testosterone.
Anderson WR; Rahimy MH; Brewster ME; Bodor N; Simpkins JW
Endocrinology; 1991 Aug; 129(2):726-33. PubMed ID: 1855470
[TBL] [Abstract][Full Text] [Related]
30. The effects of a brain-enhanced estradiol delivery system on testosterone and androgen-dependent tissues. I. Dose-response and time-course evaluation.
Rahimy MH; Anderson WR; Brewster ME; Bodor N; Simpkins JW
Endocrinology; 1991 Aug; 129(2):717-25. PubMed ID: 1855469
[TBL] [Abstract][Full Text] [Related]
31. Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway.
Yu J; Eto M; Kozaki K; Akishita M; Okabe T; Ouchi Y
Eur J Pharmacol; 2008 Jul; 589(1-3):32-6. PubMed ID: 18541231
[TBL] [Abstract][Full Text] [Related]
32. Interaction of perphenazine and an ergoline derivative on oestrogen-induced adenohypophyseal growth.
Schreiber V; Pribyl T
Physiol Bohemoslov; 1977; 26(1):31-8. PubMed ID: 140398
[TBL] [Abstract][Full Text] [Related]
33. Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms.
Black LJ; Goode RL
Endocrinology; 1981 Sep; 109(3):987-9. PubMed ID: 7262030
[TBL] [Abstract][Full Text] [Related]
34. Antagonism of androgen and estrogen effects in guinea pig seminal vesicle epithelium and fibromuscular stroma by keoxifene (LY156758).
Neubauer BL; Biser P; Jones CD; Mariotti A; Hoover DM; Thornton T; Thornton MO; Goode RL
Prostate; 1989; 15(3):273-86. PubMed ID: 2531383
[TBL] [Abstract][Full Text] [Related]
35. The antiestrogen LY117018 blocks effects of estradiol on pituitary glucose-6-phosphate dehydrogenase specific activity and on serum LH.
Gordon MN; Mobbs CV; Finch CE
Neuroendocrinology; 1985 May; 40(5):381-4. PubMed ID: 4010886
[TBL] [Abstract][Full Text] [Related]
36. Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
Markaverich BM; Alejandro MA
Int J Oncol; 1998 May; 12(5):1127-35. PubMed ID: 9538139
[TBL] [Abstract][Full Text] [Related]
37. Molecular effects of antiestrogens (tamoxifen and LY117018) on estrogen-dependent glycoprotein (USP-1) synthesized and secreted by rat uterine epithelial cells.
Takeda A; Shimizu S
Endocrinology; 1988 Jul; 123(1):258-63. PubMed ID: 3383775
[TBL] [Abstract][Full Text] [Related]
38. Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat.
Neubauer BL; Best KL; Clemens JA; Gates CA; Goode RL; Jones CD; Laughlin ME; Shaar CJ; Toomey RE; Hoover DM
Prostate; 1993; 23(3):245-62. PubMed ID: 8234067
[TBL] [Abstract][Full Text] [Related]
39. A rat prostatic adenocarcinoma as a model for the human disease.
Müntzing J; Kirdani RY; Murphy GP; Sandberg AA
Invest Urol; 1979 Jul; 17(1):37-41. PubMed ID: 447485
[TBL] [Abstract][Full Text] [Related]
40. Effects of estrogen on growth of androgen-responsive rat prostatic tumor (R 3327).
Furuya Y; Sato N; Watabe Y; Shimazaki J
Endocrinol Jpn; 1991 Feb; 38(1):67-73. PubMed ID: 1915114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
